ERRFI1, as a feedback suppressor of EGFR and ERBB2, is regulated by NAT10 in an ac4C-dependent manner, participates in the EGFR-mediated signaling pathway, and participates in tumor development and chemotherapy resistance in CRC [66]. This evidence concerns the gene NAT10 and colorectal carcinoma.